Telomir Pharmaceuticals secures $3 million investment

MIAMI - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a biotechnology firm focused on age-reversal treatments, announced today that it has received a $3 million equity investment from The Bayshore Trust, its largest shareholder. The investment involved the purchase of 1 million restricted shares at $3.00 each, an 18% premium over the closing share price on the execution date. According to InvestingPro data, TELO shares are currently trading at $2.29, near their 52-week low of $2.25, having declined nearly 60% over the past year.

This recent transaction is part of the company’s broader fundraising efforts, which include a previous $1 million investment and an untapped $5 million credit line from affiliated entities. Chairman and CEO Erez Aminov emphasized the shareholder-friendly nature of these investments, which come without warrants, discounts, or toxic features. InvestingPro analysis indicates the company operates with a moderate level of debt and currently has short-term obligations exceeding liquid assets, with a current ratio of 0.75.

The funds are aimed at supporting Telomir’s operational goals, particularly the submission of an Investigational New Drug (IND) application by year-end for Telomir-1, a drug candidate targeting rare diseases. The company’s strategy involves leveraging a rare disease indication to demonstrate Telomir-1’s clinical impact efficiently.

Telomir-1 is designed to address key biological factors of aging and chronic diseases, showing promise in preclinical models for conditions like Progeria, Type 2 diabetes, Wilson’s disease, and various oncology indications. The company plans to engage with the FDA through the Rare Disease Endpoint Advancement (RDEA) Pilot Program to further its clinical development.

Additionally, Telomir is advancing Telomir-Ag2, a novel Silver(II) compound with antimicrobial properties, particularly against drug-resistant strains. This compound has potential applications in wound care and infection prevention, addressing a market projected to exceed $30 billion.

The press release included a cautionary note on forward-looking statements, reminding readers that such statements are subject to risks and uncertainties. The company’s progress and operations are detailed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC.

This financial move is seen as a sign of insider conviction in Telomir’s potential and is based on a press release statement from the company. With a market capitalization of $75.6 million, TELO currently trades below its InvestingPro Fair Value. Investors seeking deeper insights into TELO’s financial health, including 8 additional ProTips and comprehensive valuation metrics, can access detailed analysis through InvestingPro’s advanced platform.

In other recent news, Telomir Pharmaceuticals has completed a $3 million equity financing round, selling 1 million restricted shares at a premium price. This funding, provided by The Bayshore Trust, will support regulatory and development activities for Telomir-1, the company’s drug candidate for a rare disease. The company also announced the development of Telomir-Ag2, a novel drug candidate targeting resistant bacterial infections. In preclinical studies, Telomir-Ag2 has demonstrated broad-spectrum antimicrobial activity, showing promise against methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA). Additionally, Telomir-1 has shown potential in reversing signs of cellular aging and reducing tumor growth in prostate cancer models, as well as mitigating chemotherapy-induced toxicity. These preclinical findings indicate Telomir-1’s potential to protect healthy cells from the adverse effects of chemotherapy. Telomir Pharmaceuticals is advancing its drug candidates through the regulatory process and exploring partnerships in various healthcare segments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.